Floatz logo

FILGRASTIM

Ovarian Serous Cystadenocarcinoma

University of Washingtonprotein_peptidePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Ovarian Serous Cystadenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 2BB
Metformin
University of Chicago
Phase 2BB
Hycamtin
Gynecologic Oncology Group
Phase 2B
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2B
Paclitaxel Lipid Suspension
Jina Pharmaceuticals Inc.
Phase 3B

View all 28 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →